Cargando…

Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse

Background: Primary central nervous system lymphoma (PCNSL) is a rare extranodal non-Hodgkin’s lymphoma that occurs in the central nervous system. Although sensitive to chemotherapy, 35–60% of PCNSL patients still relapse within 2 years after the initial treatment. High-dose methotrexate (HD-MTX) re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Peng, Chen, Hongyi, Shen, Li, Liu, Xiao, Wu, Xuefan, Chen, Lang, Cao, Aihong, Geng, Daoying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497740/ https://www.ncbi.nlm.nih.gov/pubmed/36135091 http://dx.doi.org/10.3390/curroncol29090522

Ejemplares similares

High-Dose Methotrexate for the Treatment of Relapsed Central Nervous System Erdheim-Chester Disease
por: Ho, Prahlad, et al.
Publicado: (2014)

Analysis of Key Clinical Variables and Radiological Manifestations Associated with the Treatment Response of Patients with Brain Metastases to Stereotactic Radiosurgery
por: Du, Peng, et al.
Publicado: (2022)

High‐dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma
por: Akiyama, Hiroki, et al.
Publicado: (2016)

Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma
por: Bernard, S., et al.
Publicado: (2021)

A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma
por: Villanueva, Gabriela, et al.
Publicado: (2023)

Prediction of treatment response in patients with brain metastasis receiving stereotactic radiosurgery based on pre-treatment multimodal MRI radiomics and clinical risk factors: A machine learning model
por: Du, Peng, et al.
Publicado: (2023)

Predicting Histopathological Grading of Adult Gliomas Based On Preoperative Conventional Multimodal MRI Radiomics: A Machine Learning Model
por: Du, Peng, et al.
Publicado: (2023)

Establishment of a Prediction Model Based on Preoperative MRI Radiomics for Diffuse Astrocytic Glioma, IDH-Wildtype, with Molecular Features of Glioblastoma
por: Du, Peng, et al.
Publicado: (2023)

Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma
por: Fan, Ni, et al.
Publicado: (2017)

Unusual relapse of primary central nervous system lymphoma
por: Igala, Marielle
Publicado: (2016)

Primary cardiac lymphoma with central nervous system relapse
por: van Rooijen, Cleo R., et al.
Publicado: (2017)

Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

Recurrence of methotrexate-induced leukoencephalopathy after methotrexate rechallenge: A case report and literature review
por: AlKawi, Ammar, et al.
Publicado: (2022)

Curative effect of methotrexate combined with teniposide in the treatment of primary central nervous system lymphoma
por: Wang, Yi-Xia, et al.
Publicado: (2020)

Salvage Therapy for Refractory Aids-Related Primary Central Nervous System Lymphoma
por: Ferro, Hugo, et al.
Publicado: (2012)

ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
por: Takezaki, Tatsuya, et al.
Publicado: (2020)

ML-04 The influence of surgical intervention for high-dose Methotrexate chemotherapy in the patients with primary central nervous system lymphoma
por: Okamoto, Michinari, et al.
Publicado: (2020)

Relapsed Primary Central Nervous System Lymphoma: Current Advances
por: Tao, Kaiyan, et al.
Publicado: (2021)

Nomogram Model for Predicting the Prognosis of High-Grade Glioma in Adults Receiving Standard Treatment: A Retrospective Cohort Study
por: Du, Peng, et al.
Publicado: (2022)

Cerebrospinal fluid metabolic markers predict prognosis behavior of primary central nervous system lymphoma with high-dose methotrexate-based chemotherapeutic treatment
por: Zhou, Liying, et al.
Publicado: (2022)

Reduced-dose whole-brain radiotherapy with tumor bed boost after upfront high-dose methotrexate for primary central nervous system lymphoma
por: Lee, Tae Hoon, et al.
Publicado: (2020)

Factors Influencing the Response to High Dose Methotrexate-based Vincristine and Procarbazine Combination Chemotherapy for Primary Central Nervous System Lymphoma
por: Sung, Kang Hyun, et al.
Publicado: (2011)

Urine volume to hydration volume ratio is associated with pharmacokinetics of high‐dose methotrexate in patients with primary central nervous system lymphoma
por: Isono, Tetsuichiro, et al.
Publicado: (2021)

Prognostic Role of Blood Markers in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate-Based Therapy
por: Luo, Qian, et al.
Publicado: (2021)

Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial
por: Scarfò, Lydia, et al.
Publicado: (2022)

Successful therapeutic rechallenge after a severe episode of high dose methotrexate-induced choreoathetosis: A case report
por: Chong, Lip Leong, et al.
Publicado: (2019)

Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma
por: Sun, Xuefei, et al.
Publicado: (2017)

The risk of central nervous system relapses in patients with peripheral T-cell lymphoma
por: Chihara, Dai, et al.
Publicado: (2018)

Central Nervous System Progression/Relapse in Mature T- and NK-Cell Lymphomas
por: Bhansali, Rahul S., et al.
Publicado: (2023)

Treatment of Recurrent Posttransplant Lymphoproliferative Disorder of the Central Nervous System with High-Dose Methotrexate
por: Twist, Clare J., et al.
Publicado: (2013)

Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi
por: Kaimila, Bongani, et al.
Publicado: (2017)

Hyperosmolar and methotrexate therapy avoiding surgery in the acute presentation of primary central nervous system lymphoma
por: Lee, Bryan S., et al.
Publicado: (2014)

Successful rapid drug desensitization to methotrexate in a patient with primary central nervous system lymphoma
por: Song, Kyung Mee, et al.
Publicado: (2018)

Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma
por: Fujimoto, Kenji, et al.
Publicado: (2020)

Primary Central Nervous System T-cell Lymphoma as Methotrexate-associated Lymphoproliferative Disorders: Case Report
por: KAWANO, Hiroto, et al.
Publicado: (2021)

High‐dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China
por: Chen, Cui, et al.
Publicado: (2019)

Low-Dose Whole Brain Radiotherapy with Tumor Bed Boost after Methotrexate-Based Chemotherapy for Primary Central Nervous System Lymphoma
por: Kim, Byoung Hyuck, et al.
Publicado: (2014)

Advantages of Dose-Dense Methotrexate Protocol for Primary Central Nervous System Lymphoma: Comparison of Two Different Protocols at a Single Institution
por: Aoki, Hiroshi, et al.
Publicado: (2013)

High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma
por: Ong, Shin Yeu, et al.
Publicado: (2021)

P1217: INTRATHECAL METHOTREXATE PROPHYLAXIS AND CENTRAL NERVOUS SYSTEM RELAPSE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH INTENSIFIED R-ACVBP STRATEGY
por: Renaud, L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9ato7detnf11bjutl8m0171b35